ATE214603T1 - Stabile makrolide und makrolide imptstoff- zusammensetzungen - Google Patents

Stabile makrolide und makrolide imptstoff- zusammensetzungen

Info

Publication number
ATE214603T1
ATE214603T1 AT96304702T AT96304702T ATE214603T1 AT E214603 T1 ATE214603 T1 AT E214603T1 AT 96304702 T AT96304702 T AT 96304702T AT 96304702 T AT96304702 T AT 96304702T AT E214603 T1 ATE214603 T1 AT E214603T1
Authority
AT
Austria
Prior art keywords
macrolides
macrolide
stable
vaccine compositions
vaccine
Prior art date
Application number
AT96304702T
Other languages
English (en)
Inventor
Ramune Marija Cobb
Christopher Leigh Schwartzkoff
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE214603(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE214603T1 publication Critical patent/ATE214603T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/843—Corynebacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT96304702T 1995-06-30 1996-06-26 Stabile makrolide und makrolide imptstoff- zusammensetzungen ATE214603T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60595P 1995-06-30 1995-06-30

Publications (1)

Publication Number Publication Date
ATE214603T1 true ATE214603T1 (de) 2002-04-15

Family

ID=21692234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96304702T ATE214603T1 (de) 1995-06-30 1996-06-26 Stabile makrolide und makrolide imptstoff- zusammensetzungen

Country Status (15)

Country Link
US (2) US5989566A (de)
EP (1) EP0750907B1 (de)
AR (1) AR003445A1 (de)
AT (1) ATE214603T1 (de)
AU (1) AU708464B2 (de)
BR (1) BR9602939A (de)
DE (1) DE69619894T2 (de)
DK (1) DK0750907T3 (de)
ES (1) ES2174027T3 (de)
NZ (1) NZ286896A (de)
PT (1) PT750907E (de)
RU (1) RU2213574C2 (de)
SI (1) SI0750907T1 (de)
UY (2) UY24268A1 (de)
ZA (1) ZA965539B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037178A2 (en) * 1995-05-17 1996-11-28 The International Centre Of Insect Physiology And Ecology (Icipe) Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
EP0928136B1 (de) 1996-06-05 2003-10-22 Ashmont Holdings Limited Injizierbare zusammensetzungen
US6790445B1 (en) 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
JP2002515056A (ja) * 1997-02-06 2002-05-21 メルク エンド カンパニー インコーポレーテッド ワクチン用チメロサールフリー保存剤
AR013202A1 (es) * 1997-07-10 2000-12-13 Biotech Australia Pty Ltd Vacunas no acuosas
US6524592B2 (en) * 1997-10-17 2003-02-25 American Home Products Corporation Veterinary vaccines
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1588167A4 (de) * 2003-01-16 2006-08-09 Univ Virginia Spermaspezifische lysozymähnliche proteine
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
NZ529177A (en) * 2003-10-24 2005-12-23 Agres Ltd Administration process for a delivery device that releases the active agent over several days
BRPI0416205A (pt) * 2003-11-21 2006-12-26 Pfizer Prod Inc uso de antibióticos como adjuvantes de vacina
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
WO2007126816A2 (en) * 2006-03-30 2007-11-08 Embrex, Inc. Methods and compositions for vaccination of poultry
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090053335A1 (en) * 2007-04-13 2009-02-26 Chih-Hui Lin Herbal compositions for the inhibition of human immunodeficiency virus (hiv)
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009012924A (es) * 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
EP2723378A4 (de) * 2011-06-24 2015-01-28 Epitogenesis Inc Pharmazeutische zusammensetzungen mit einer kombination aus ausgewählten trägern, vitaminen, tanninen und flavonoiden als antigenspezifischen immunmodulatoren
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
SU627612A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат земл ковой в.п. против клюстридиозов животных и птиц
NZ193807A (en) * 1979-05-31 1983-03-15 Ici Tasman Ltd Improving the response of ruminants to clostridial vaccine by administering tetramisole or levamisole
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS62294623A (ja) * 1986-02-26 1987-12-22 Nisshin Flour Milling Co Ltd サルモネラ感染症予防剤
DE3786025T2 (de) * 1986-03-12 1993-10-14 American Cyanamid Co Makrolid-Verbindungen.
RU2024527C1 (ru) * 1986-03-25 1994-12-15 Санкио Компани Лимитед Способ получения макролидных соединений
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
US4988824A (en) * 1989-09-11 1991-01-29 Maulding Donald R Process for the preparation of 23-(C1-C6 alkyloxime)-LL-F28249 compounds
FR2654339B1 (fr) * 1989-11-14 1994-10-28 Mayoly Spindler Laboratoires Nouveaux derives solubles et non toxiques des macrolides polyeniques basiques, leur preparation et leurs applications.
US5262400A (en) * 1991-06-20 1993-11-16 Merck & Co., Inc. 4α-substituted avermectin derivatives
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
EP0750907B1 (de) 2002-03-20
NZ286896A (en) 1998-05-27
US5989566A (en) 1999-11-23
EP0750907A2 (de) 1997-01-02
PT750907E (pt) 2002-08-30
AR003445A1 (es) 1998-08-05
UY24281A1 (es) 1996-12-26
ES2174027T3 (es) 2002-11-01
DE69619894D1 (de) 2002-04-25
AU708464B2 (en) 1999-08-05
US20020102266A1 (en) 2002-08-01
RU2213574C2 (ru) 2003-10-10
DK0750907T3 (da) 2002-07-08
ZA965539B (en) 1998-03-30
SI0750907T1 (en) 2002-08-31
UY24268A1 (es) 2001-10-25
DE69619894T2 (de) 2002-11-14
BR9602939A (pt) 1998-04-22
EP0750907A3 (de) 1998-05-06
US6746677B2 (en) 2004-06-08
AU5625696A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
DE69619894D1 (de) Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
IT1288395B1 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
EE03976B1 (et) Erütromütsiinid ja nende valmistamise meetod
ATE357252T1 (de) Adjuvanzsysteme und impfstoffe
ATE310742T1 (de) C-4ß-SUBSTITUTIERTE MACROLID-DERIVATE
FI951003L (fi) Erytromysiinin ja atsitromysiinin 3"-desmetoksijohdannaiset
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
IS5251A (is) 9-oxím erýþrómýsín afleiður
DE69630221D1 (de) Stabile alkoholisch-wässrige zusammensetzung
HUP0104489A3 (en) Stabilizated macrolides and pharmaceutical compositions containing them
DE69730092D1 (de) Photovernetzbare Siliconzusammensetzungen
DE69619826D1 (de) Abtastvorrichtung und verfahren
EE9800123A (et) Stabiilsed lüofiliseeritud ravimvormid
DE60001676D1 (de) Silikongelzusammensetzung und daraus hergestelltes Silikongel
DE69409309D1 (de) Stabile dispergierbare Siliconzusammensetzungen
ATE308990T1 (de) Stabile fsh und fsh varianten enthaltende arzneimitteln
DE69605094D1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
NO980016D0 (no) Makrolider
DK1027362T3 (da) 2-halogen-6-O-substituerede ketolidderivater
EP0744443A3 (de) Härtbare Siliconzusammensetzung
BR9510277A (pt) Composições de silicone
EP0727462A3 (de) Silicongelzusammensetzung
DE69715951D1 (de) Dispergierbare Siliconzusammensetzungen
LV11898A (lv) Eritromicina atvasinajumi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification